Posted by Michael Wonder on 09 Apr 2025
Catalyst Pharmaceuticals announces Health Canada’s acceptance of Agamree new drug submission with priority review
8 April 2025 - Catalyst Pharmaceuticals today reported that its sub-licensee in Canada, Kye Pharmaceuticals has announced that Health Canada has accepted the new drug submission for Agamree, a novel corticosteroid treatment for Duchenne muscular dystrophy for review.
The submission has been granted priority review, expediting the regulatory process with the potential for marketing authorisation before the end of 2025.
